SUMMARY In a prospective 24 week study of 25 patients with rheumatoid arthritis (RA) weekly intramuscular (IM) sodium aurothiomalate resulted in a small but significant reduction in the circulating lymphocyte count. Analysis of absolute levels of pan T cells, T4 helper cells, T8 suppressor cells, T4/8 ratio, B cells, and major histocompatibility complex (MHC) class II positive cells showed reductions in these subsets, though these changes did not reach significance. At entry there was no association between circulating lymphocyte counts and subsets and clinical and laboratory indices which reflected disease activity, and during the study gold responders could not be differentiated from non-responders with regard to changes in lymphocyte counts and subsets. Thus this study suggests that weekly IM gold leads to a modest reduction in circulating lymphocyte numbers which involves most subsets. This effect appears to be independent of the clinical efficacy of this drug.
The mechanism for the efficacy of chrysotherapy in the suppression of rheumatoid inflammation is poorly understood. A large variety of effects on cellular and humoral immune parameters have been noted, but the relevance and interrelationship of these changes are unclear. A recent report has recorded a fall in circulating lymphocyte numbers in 10 patients with RA in response to gold therapy.'
The fall was substantial (40% of initial lymphocyte count) with the nadir occurring 10-12 weeks after the start of gold therapy and appeared to involve all lymphocyte subsets studied. 2 The authors concluded that the suppressive effects of gold therapy on circulating lymphocyte numbers might allow new and novel insights into the mechanism of action of gold salts in RA globulins. There was no significant difference during the study between the fall in lymphocyte numbers and subsets and the response to gold therapy, i.e., the declines were observed in both groups to similar degrees (Table 2 ). When the data were analysed excluding data for the two patients given pulse methylprednisolone in the first week of the study (n=23) the results were the same as when they were included (n=25), and in particular the transient smaller fall in lymphocyte numbers between weeks 0 and 6 was still apparent.
Discussion
This study has shown that weekly IM gold in RA leads to a small (maximum of 20%) reduction of circulating lymphocyte counts which appears to affect cell subsets studied and occurs in both gold responders and non-responders. Thus this study has confirmed the conclusion of Hassan et al, 2 though the magnitude of the fall seen in our study was smaller.
The mechanism for the reduction of the circulating lymphocyte count is unknown. As it affects most subsets, including the T8 subset which is relatively deficient in RA and appears to be independent of the therapeutic efficacy of gold, it probably has little clinical relevance. As most subsets were affected in a non-selective and time dependent fashion we suggest that sodium aurothiomalate suppresses lymphopoiesis rather than causing redistribution of circulating lymphocytes, though we cannot exclude the possibility that gold is shortening the lymphocyte half life. We also noted in certain individuals that the fall in lymphocyte count was more pronounced while in others it was minimal or not apparent, and this effect did not correlate with clinical outcome.
This suggests that individuals vary in their susceptibility to this gold effect.
It was noted in this study that there was a substantial and significant fall in RF levels (and to a lesser extent IgM, data not shown), while there were no significant changes in circulating surface membrane immunoglobulin positive B lymphocyte numbers. There are a number of possible explanations for this apparent paradox but one of interest is the possibility that gold salts have a selective suppressive effect on the B subpopulation that produces RF (e.g., CD5 positive B lymphocytes). This possibility is currently under investigation. 
